ARCHIVES

Alimta Granted Approval As NSCLC Continuation Therapy

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

Senate Committee Adds $100 Million for Cancer, Earmarks Extra Positions for NCI, Backs New Construction

September 19, 1975

NCI Appropriations, Authorization Bills Passed By House

September 5, 1980

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

May 6, 2005

NCA Approves Major Revision In Program Project Guidelines; Smaller, Tightly Focused Grants Seen

May 27, 1983

CMS Withholds Coverage of CT Colonography

May 15, 2009

List of 100 Highest-Paid NIH Officials

February 12, 2010